The first-in-human phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas.

Atsushi NatsumeYoshiki Arakawa Yoshitaka NaritaKazuhiko SugiyamaNobuhiro HataYoshihiro MuragakiNaoki ShinojimaToshihiro KumabeRyuta SaitoKazuya MotomuraYohei MineharuYasuji MiyakitaFumiyuki YamasakiYuko MatsushitaKoichi IchimuraKazumi ItoMasaya TachibanaYasuyuki KakuraiNaoko OkamotoTakashi AsahiSoichiro NishijimaTomoyuki YamaguchiHiroshi TsubouchiHideo NakamuraRyo Nishikawa

Published in: Neuro-oncology (2022)

DS-1001 was well-tolerated with a favorable brain distribution. Recurrent/progressive IDH1-mutant glioma patients responded to treatment. A study of DS-1001 in patients with chemotherapy- and radiotherapy-naïve IDH1-mutated WHO grade 2 glioma is ongoing (NCT04458272).

Keyphrases

wild type
low grade
multiple sclerosis
end stage renal disease
white matter
high grade
endothelial cells
locally advanced
ejection fraction
resting state
chronic kidney disease
early stage
prognostic factors
radiation therapy
radiation induced
cerebral ischemia
rectal cancer
blood brain barrier
smoking cessation